Home / Themes / Biotech '25: RNA Therapeutics
Last updated
Theme thesis · 3/5 sections · Tickers 4 with notes · 14 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Companies developing and commercializing medicines that manipulate RNA to silence disease-causing genes, alter RNA splicing, edit RNA sequences or deliver instr
Companies developing and commercializing medicines that manipulate RNA to silence disease-causing genes, alter RNA splicing, edit RNA sequences or deliver instructions for therapeutic protein production. The basket spans siRNA, antisense oligonucleotides, mRNA and RNA editing platforms. Competitive advantages arise from proprietary oligonucleotide chemistry, tissue-specific delivery, intracellular uptake, durable target engagement, manufacturing capabilities and clinical validation. Expansion beyond rare diseases into cardiovascular, metabolic, neurological and oncological conditions increases the commercial relevance of RNA-based medicines.
Improved GalNAc conjugates, antibody-oligonucleotide delivery, peptide carriers and lipid nanoparticles enable RNA medicines to reach muscle, brain and other extrahepatic tissues, expanding the number of treatable molecular targets.
Commercial success of RNAi and antisense medicines in cardiovascular and metabolic diseases supports expansion from small inherited-disease populations into larger chronic indications, increasing product revenue opportunities and validating repeat-dosing models.
Clinical validation of RNA editing, splice correction and advanced mRNA delivery creates new therapeutic approaches for diseases inadequately addressed by conventional small molecules, antibodies or permanent DNA editing.
Inadequate tissue delivery, inefficient endosomal escape, off-target gene silencing and dose-dependent toxicities limit therapeutic efficacy, particularly outside the liver where successful delivery remains difficult.
Competing gene therapies, gene-editing technologies and conventional pharmaceuticals produce more durable or convenient outcomes, while repeated dosing, manufacturing costs and payer scrutiny reduce the commercial competitiveness of RNA medicines.
Failures in pivotal clinical trials, immunogenicity, unexpected long-term safety effects or regulatory concerns regarding novel RNA editing mechanisms delay commercialization, while patent disputes and concentrated development partnerships weaken platform economics.
Discussions on Next Generation Sequencing technologies, bioinformatics, and platform-agnostic applications.
Bioinformatics Q&A, tutorials, and tools, indicating trends in data analysis for genetic medicine.
Community discussions and news sharing related to synthetic biology advancements and challenges.
Discussions specifically on Next Generation Sequencing technologies and applications.
Professional discussions on RNA therapeutics, gene editing, and related industry developments.
Matchedfred · access=api · map_only
Metric/field DFF
Cadence monthly
Why it matters Higher interest rates increase the cost of capital for R&D-intensive biotech companies, impacting funding for pipeline development and expansion.
Signal to watch Rising rates are generally bearish, while stable or falling rates are bullish for growth-oriented biotech.
Confidence: high
Not in registry
Metric/field Global VC Funding - Biotechnology
Cadence quarterly
Why it matters Venture capital funding is a critical source of capital for biotech companies, especially those in early to mid-stage development, indicating investor confidence and available growth capital.
Signal to watch Increasing funding indicates strong investor appetite and market growth, which is bullish.
Confidence: high
Matched (medium)fred · access=api · map_only
Metric/field CUUR0000SAM2
Cadence monthly
Why it matters The CPI for medical care services reflects healthcare inflation, which can influence pricing power, reimbursement rates, and overall healthcare spending, directly impacting biotech revenue potential.
Signal to watch Stable or moderately increasing medical care CPI is generally neutral to bullish, while rapid increases could signal payer pressure.
Confidence: medium
Not in registryaccess=api
Metric/field M313254
Cadence monthly
Why it matters Shipments of drugs and medicines provide a broad indicator of activity and demand within the pharmaceutical and biotech manufacturing sector, reflecting overall industry health.
Signal to watch Consistent growth in shipments is bullish, indicating robust demand and production.
Confidence: medium
Matched (medium)lab_headcount · access=api
Metric/field CES3254000001
Cadence monthly
Why it matters Employment trends in pharmaceutical and medicine manufacturing reflect investment in the sector's workforce, R&D capacity, and production capabilities, signaling growth or contraction.
Signal to watch Sustained growth in employment is bullish, indicating expansion and confidence in future prospects.
Confidence: medium
Not in registry
Metric/field Study Status for NCT IDs (e.g., ARO-DIMER-PA, ARO-MAPT, ARO-INHBE, ARO-ALK7)
Cadence event_driven
Why it matters Monitoring the 'Study Status' for key pipeline assets (like Arrowhead's ARO-DIMER-PA, ARO-MAPT, ARO-INHBE, ARO-ALK7) provides real-time updates on trial progress, recruitment, and completion, which are critical milestones for RNA-based therapies.
Signal to watch Advancement to later phases or successful completion is bullish; delays or terminations are bearish.
Confidence: high
Not in registry
Metric/field New Drug Approvals (specific drug names like plozasiran)
Cadence event_driven
Why it matters FDA approvals are the ultimate validation for new RNA-based medicines, directly impacting market entry and revenue generation. Tracking sNDA submissions (e.g., Arrowhead's plozasiran for sHTG) and approvals is crucial.
Signal to watch Approval or accelerated review is bullish; delays or rejections are bearish.
Confidence: high
Not in registry
Metric/field Publication Count for 'RNA interference therapeutics' AND 'AI drug discovery'
Cadence monthly
Why it matters Trends in scientific publications reflect the pace of innovation and research activity in core theme areas like RNA interference and AI-driven drug discovery, indicating the health and future potential of the field.
Signal to watch Increasing publication counts suggest a growing and active research landscape, which is bullish for long-term innovation.
Confidence: medium
Not in registry
Metric/field Disease Outbreak Alerts
Cadence weekly
Why it matters Global health events and emerging infectious diseases can drive demand for rapid diagnostic tools and vaccine development, areas where companies like Twist Bioscience (viral panels) can play a significant role.
Signal to watch Increased alerts for novel or rapidly spreading pathogens can be bullish for companies providing rapid genomic response tools.
Confidence: low
Not in registry
Metric/field Press Releases - Clinical Trial Results / Regulatory Filings
Cadence event_driven
Why it matters Direct company announcements provide the most immediate and official updates on clinical trial data readouts, regulatory milestones, and strategic partnerships, which are key value drivers for biotech.
Signal to watch Positive clinical data or regulatory advancements are bullish; negative outcomes or delays are bearish.
Confidence: high
Matched (medium)spherix_global_insights_physician_surveys · access=file · map_only
Metric/field Physician Survey Results - Novel Hypertriglyceridemia Treatments - Perceived Efficacy/Safety/Dosing
Cadence irregular
Why it matters Physician perception and prescribing intent for new therapies like Arrowhead's REDEMPLO in severe hypertriglyceridemia are crucial for market adoption and sales forecasts, especially given competitive pressures.
Signal to watch High perceived efficacy, favorable safety, and convenient dosing for REDEMPLO are bullish.
Confidence: high
Not in registry
Metric/field Competitive Landscape Analysis - RNAi Therapies for Cardiometabolic Diseases - Pipeline Stage/Market Share Projections
Cadence quarterly
Why it matters Understanding the competitive landscape, including other RNAi therapies and GLP-1s, is vital for assessing market share potential and pricing power for Arrowhead's cardiometabolic franchise.
Signal to watch Favorable competitive positioning and strong market share projections are bullish.
Confidence: high
Matchediqvia_prescription_rx_data · access=file · map_only
Metric/field NGS Diagnostic Market Share - Molecular Residual Disease (MRD) Testing - Vendor Breakdown
Cadence irregular
Why it matters Market share data for NGS diagnostic panels, particularly in high-growth areas like molecular residual disease (MRD) testing, directly indicates Twist Bioscience's success in diversifying its revenue streams.
Signal to watch Increasing market share for Twist's NGS offerings in MRD is bullish.
Confidence: high
Matched (medium)s_p_global_trade_supply_chain_data · access=file · map_only
Metric/field Consensus Adjusted EBITDA Estimates - TWST
Cadence irregular
Why it matters Tracking consensus adjusted EBITDA estimates for Twist Bioscience is critical for assessing its path to profitability and operational efficiency, a key focus for management and investors.
Signal to watch Upward revisions to EBITDA estimates or consistent achievement of breakeven are bullish.
Confidence: high
Matched (medium)norstella_drug_forecasts_commercial_intelligence · access=file · map_only
Metric/field RNA-Based Therapeutics Pipeline Database - Phase III/Approved Drugs - Forecasted Sales
Cadence irregular
Why it matters Comprehensive market forecasts for the broader RNA-based therapeutics space provide a macro view of the theme's growth potential and identify emerging opportunities and competitive threats.
Signal to watch Increasing forecasted sales for the overall RNA-based therapeutics market is bullish for the theme.
Confidence: high
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| NVO_71e5b33d | at the end of 2026 | 2026-10-01 | 2026-12-31 | FDA regulatory decision for CagriSema in the U.S. for obesity. | Approval would introduce a new, potentially highly effective obesity treatment, strengthening Novo Nordisk's pipeline and competitive position. | Ticker | 2026-05-06 | earnings_transcript | NVO (ticker) |
| ALNY_42172ed3 | in October | 2026-10-01 | 2026-10-31 | Presentation of initial Phase I results of ALN-HTT02 in patients with Huntington's disease at EHDN. | Positive safety and efficacy data (e.g., >50% huntingtin knockdown) would de-risk this program and could significantly impact the long-term growth prospects and investor sentiment for ALNY's neuroscience pipeline. | Ticker | 2026-07-30 | earnings_transcript | ALNY (ticker) |
| ALNY_e966b7db | Q4 2026 for decision, late 2026 or early 2027 for launch | 2026-10-01 | 2027-03-31 | Potential U.S. regulatory approval for cemdisiran in generalized myasthenia gravis, a partnered product with Regeneron. | Approval would enable commercialization, leading to potential milestone payments and royalties for Alnylam, contributing to collaboration and royalty revenue. | Ticker | 2026-02-12 | earnings_transcript | ALNY (ticker) |
| ALNY_1f8d0ad4 | second half of the year | 2026-07-01 | 2026-12-31 | Release of Phase 1 clinical data for ALN-HTT02 (Huntington's disease program). | Data on huntingtin protein lowering and safety are crucial for de-risking this program, which targets a devastating disease with no approved therapies, potentially accelerating its development and impacting long-term valuation. | Ticker | 2026-02-12 | earnings_transcript | ALNY (ticker) |
| ALNY_6acd0085 | second half of the year | 2026-07-01 | 2026-12-31 | Release of Phase 1 clinical data for ALN-2232 (ACVR1C targeting for obesity & weight management). | Positive data would de-risk the program, demonstrating its potential for durable weight loss and addressing unmet needs in the overweight/obesity and diabetes space, impacting long-term valuation. | Ticker | 2026-02-12 | earnings_transcript | ALNY (ticker) |
| ALNY_5d72b867 | H2 2026 | 2026-07-01 | 2026-12-31 | Readout of Phase 3 CARDIO-TTRansform study results for Ionis Pharmaceuticals' eplontersen in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). | Positive results could introduce a new competitive TTR silencer into the ATTR-CM market, potentially impacting Amvuttra's market share, pricing dynamics, and overall TTR franchise growth. | Theme | 2026-02-12 | earnings_transcript | ALNY (ticker) |
| ALNY_94ae948c | second half of the year | 2026-07-01 | 2026-12-31 | Release of Phase 1 and 2 clinical data from the ALN-6400 program (targeting plasminogen for bleeding disorders). | Positive data would de-risk the program, supporting its 'pipeline-in-a-product' potential and future development in a range of bleeding disorders, impacting long-term valuation. | Ticker | 2026-02-12 | earnings_transcript | ALNY (ticker) |
| WVE_fecf2e7a | after that meeting (meeting 'end of summer') | 2026-09-01 | 2026-10-31 | Receipt of FDA feedback following a meeting to discuss a potential accelerated approval pathway for WVE-006 in Alpha-1 Antitrypsin Deficiency. | This feedback is critical for defining the registrational study design and timeline for WVE-006, potentially accelerating its path to market and validating Wave's RNA editing platform. | Ticker | 2026-07-30 | earnings_transcript | WVE (ticker) |
| WVE_3a372b71 | second half of this year | 2026-09-01 | 2026-12-31 | Release of clinical data from the 600-milligram monthly dosing cohort of the RestorAATion-2 trial for WVE-006 in Alpha-1 Antitrypsin Deficiency. | This data will help inform the optimal dose regimen for WVE-006 and provide further evidence of its therapeutic profile, which is crucial for its registrational plans and potential accelerated approval. | Ticker | 2026-07-30 | earnings_transcript | WVE (ticker) |
| WVE_a34877eb | later this year | 2026-09-01 | 2026-12-31 | Clinical Trial Application (CTA) submission for WVE-008 for the treatment of homozygous PNPLA3 I148M liver disease. | This submission marks the advancement of Wave's second RNA editing candidate into clinical development, expanding its pipeline and validating the platform's broader applicability in addressing high unmet needs in liver diseases. | Ticker | 2026-07-30 | earnings_transcript | WVE (ticker) |
| WVE_29e0b824 | later this year | 2026-09-01 | 2026-12-31 | Initiation of additional Phase II clinical trials for WVE-007, evaluating its potential in combination with incretins and as a post-incretin maintenance therapy for obesity. | These trials expand the development program for WVE-007 into new, commercially significant market segments, potentially differentiating it from existing obesity treatments and enhancing its market opportunity. | Ticker | 2026-07-30 | earnings_transcript | WVE (ticker) |
| WVE_8fe27c5d | this year | 2026-09-01 | 2026-12-31 | Release of additional Phase I INLIGHT clinical data for WVE-007, specifically including results from the 600-milligram cohort. | This data will provide further insights into the durability and efficacy of WVE-007 at a higher dose, which could strengthen its competitive profile and inform future development strategies in obesity. | Ticker | 2026-07-30 | earnings_transcript | WVE (ticker) |
| WVE_2167fb27 | in 2026 | 2026-01-01 | 2026-12-31 | Submission of a New Drug Application (NDA) for accelerated approval of N531 with a monthly dosing regimen for Duchenne Muscular Dystrophy (DMD). | An NDA submission would be a significant step towards commercialization for N531, potentially offering a new treatment option for DMD patients and generating revenue for Wave. | Ticker | 2026-02-26 | earnings_transcript | WVE (ticker) |
| WVE_87860d6a | in 2026 | 2026-01-01 | 2026-12-31 | Initiation of new clinical trials evaluating WVE-007 as an incretin add-on and as a post-incretin maintenance therapy. | These trials could position WVE-007 as a complementary or alternative therapy to GLP-1s, addressing unmet needs in tolerability, muscle preservation, and long-term weight management, potentially expanding its commercial potential. | Ticker | 2026-02-26 | earnings_transcript | WVE (ticker) |
| WVE_588bde35 | in 2026 and beyond | 2026-01-01 | 2026-12-31 | Receipt of additional milestone payments from the research collaboration with GSK as programs advance. | These milestone payments provide non-dilutive funding, validate Wave's PRISM platform, and contribute to the company's cash runway, supporting its R&D efforts. | Ticker | 2026-02-26 | earnings_transcript | WVE (ticker) |
